Regulus Therapeutics Inc RGLS

NAS: RGLS | ISIN: US75915K2006   17/05/2024
2,000 USD (0,00%)
(0,00%)   17/05/2024
Grafiek Regulus Therapeutics Inc Grafiek Regulus Therapeutics Inc

Regulus Therapeutics Inc in het nieuws

16 mei 2024 · Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer · Persbericht

9 mei 2024 · Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates · Persbericht

6 mei 2024 · Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

30 april 2024 · Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series · Persbericht

21 maart 2024 · Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

2 januari 2024 · Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

9 november 2023 · Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates · Persbericht

2 november 2023 · Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

Profiel Regulus Therapeutics Inc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Website: www.regulusrx.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Joseph Hagan

Werknemers: 47

Aandelen Regulus Therapeutics Inc

Beurswaarde: 130,93 miljoen USD

Effecten: 65,47 miljoen

Beta: 1,64

Mijn selecties